Welcome to our dedicated page for Recursion Pharmaceuticals SEC filings (Ticker: RXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Recursion Pharmaceuticals’ disclosures can feel as intricate as the biology it decodes—hundreds of pages on R&D spend, partnership revenue, and stock dilution that even seasoned analysts find overwhelming. If you have ever searched for “Recursion Pharmaceuticals SEC filings explained simply” or wished for a “Recursion Pharmaceuticals annual report 10-K simplified,” this page was built for you.
Stock Titan’s AI reads every 10-K, 10-Q, 8-K, Form 4, and DEF 14A the instant it lands on EDGAR, then translates the legal and scientific language into clear takeaways. Need the “Recursion Pharmaceuticals quarterly earnings report 10-Q filing” fast? Our AI pinpoints pipeline updates and burn rate within seconds. Want instant alerts on “Recursion Pharmaceuticals Form 4 insider transactions real-time”? We stream them live, flagging notable buys and sells. Each document receives an executive summary, key financial ratios, and context that turns raw data into insight—perfect for understanding Recursion Pharmaceuticals SEC documents with AI.
Why focus on RXRX? Its filings reveal critical signals: shifting clinical-trial timelines disclosed in 8-K material events, milestone payments from collaborators buried in footnotes, and “Recursion Pharmaceuticals proxy statement executive compensation” that details incentives aligned with AI-driven discovery. With our platform you can:
- Track “Recursion Pharmaceuticals insider trading Form 4 transactions” and executive stock transactions Form 4
- Dive into a Recursion Pharmaceuticals earnings report filing analysis without parsing dense exhibits
- Monitor cash runway and R&D intensity straight from quarterly numbers
Every update arrives in real time, backed by AI-powered summaries and expert commentary, so you spend minutes—not hours—extracting what matters most about this pioneering TechBio company.
Recursion Pharmaceuticals (RXRX) director Blake Borgeson received new equity compensation grants on June 18, 2025. The insider was awarded:
- 22,016 restricted stock units (RSUs) that will vest on the earlier of June 18, 2026, or the day before the 2026 Annual Meeting
- 44,031 stock options with an exercise price of $5.11, exercisable under the same vesting schedule as the RSUs
Following these transactions, Borgeson directly owns 7,089,863 shares of Class A Common Stock plus the newly granted options. The equity grants were made automatically pursuant to the company's Outside Director Compensation Policy. All awards are subject to continued service requirements. The filing was submitted by Jonathan Golightly as attorney-in-fact on June 23, 2025.
Recursion Pharmaceuticals (RXRX) director Franziska Michor received new equity compensation on June 18, 2025, consisting of two components:
- 22,016 restricted stock units (RSUs) granted under the Outside Director Compensation Policy, which will vest on the earlier of June 18, 2026, or the day before the 2026 Annual Meeting
- 44,031 stock options with an exercise price of $5.11, exercisable until June 18, 2035, vesting on the same schedule as the RSUs
Following these transactions, Michor directly owns 127,053 shares of Class A Common Stock and 44,031 stock options. Both grants are subject to continued service as a director. This filing represents standard board of director equity compensation and indicates the company's commitment to aligning director interests with shareholders through equity-based compensation.
Recursion Pharmaceuticals (RXRX) Director Robert Hershberg received new equity compensation grants on June 18, 2025. The awards consist of:
- 22,016 restricted stock units (RSUs) that will vest on the earlier of June 18, 2026, or the day before the 2026 Annual Meeting
- Stock options to purchase 44,031 shares at an exercise price of $5.11 per share, vesting on the same schedule as the RSUs
Following these transactions, Hershberg directly owns 73,732 shares of Class A Common Stock and 44,031 stock options. These equity grants were made automatically under the company's Outside Director Compensation Policy and are subject to continued service requirements. The filing indicates standard insider trading reporting compliance under Section 16(a) of the Securities Exchange Act.
Recursion Pharmaceuticals (RXRX) Director Zavain Dar received new equity compensation grants on June 18, 2025, consisting of:
- 22,016 restricted stock units (RSUs) that will vest on the earlier of June 18, 2026, or the day before the 2026 Annual Meeting
- 44,031 stock options with an exercise price of $5.11, exercisable until June 18, 2035, vesting on the same schedule as the RSUs
Following these transactions, Dar directly owns 132,893 shares of Class A Common Stock and 44,031 stock options. Both grants are subject to continued service as a director. These awards were automatically granted according to the company's Outside Director Compensation Policy, representing standard board compensation arrangements.
Recursion Pharmaceuticals director Namandje Bumpus received new equity compensation grants on June 18, 2025, consisting of:
- 11,008 restricted stock units (RSUs) that will vest on the earlier of June 18, 2026, or the day before the 2026 Annual Meeting
- 22,016 stock options with an exercise price of $5.11, exercisable until June 18, 2035, vesting on the same schedule as the RSUs
Following these transactions, Bumpus directly owns 47,557 shares of Class A Common Stock and 22,016 stock options. Both grants are subject to continued service as a director. These equity awards were automatically granted according to the company's Outside Director Compensation Policy, representing standard board compensation rather than open market transactions.
Dean Y. Li, Director at Recursion Pharmaceuticals (RXRX), reported significant insider transactions on June 18, 2025:
- Acquired 22,016 restricted stock units (RSUs) at $0, which vest on June 18, 2026 or before the 2026 Annual Meeting
- Received 44,031 stock options with exercise price of $5.11, expiring June 18, 2035
Li's total beneficial ownership includes:
- 1,234,618 shares held directly (including 1,132,815 shares transferred from GRAT)
- 1,980,029 shares held indirectly through various trusts: - 1,422,048 via Revocable Trust - 136,981 via GRAT - 421,000 via Family Trust
These grants were made automatically under the company's Outside Director Compensation Policy, subject to continued service.
Recursion Pharmaceuticals (RXRX) director Elaine D. Sun received new equity compensation grants on June 18, 2025, consisting of:
- 11,008 restricted stock units (RSUs) that will vest on the earlier of June 18, 2026, or the day before the 2026 Annual Meeting
- 22,016 stock options with an exercise price of $5.11, exercisable until June 18, 2035, vesting on the same schedule as the RSUs
Following these transactions, Sun directly owns 47,557 shares of Class A Common Stock and 22,016 stock options. Both grants are subject to continued service as a director. These equity awards were automatically granted according to the company's Outside Director Compensation Policy, representing standard board compensation arrangements.
Ben R Taylor, Chief Financial Officer of Recursion Pharmaceuticals (RXRX), reported multiple securities transactions and holdings in a Form 4 filing:
Key Transaction: On June 16, 2025, Taylor disposed of 7,057 shares of Class A Common Stock at $4.92 per share through a tax withholding transaction (F code) related to RSU settlement. Following this transaction, Taylor directly owns 823,134 shares.
Stock Option Holdings:
- 70,037 options at $7.25 (expires 2035)
- 740,686 options at $6.09 (expires 2034)
- 81,154 options at $0.14 (expires 2031)
- 92,748 options at $0.06 (expires 2031)
- 289,837 options at $0.04 (expires 2030)
All options have various vesting schedules ranging from monthly to annual installments, subject to continued service requirements.
Recursion Pharmaceuticals held its 2025 Annual Meeting on June 18, with stockholders voting on three key proposals. All proposals passed successfully.
Key outcomes include:
- Election of three Class I directors to serve until 2028: - Zachary Bogue (242.3M votes for) - Zavain Dar (203.3M votes for) - Robert Hershberg (233.5M votes for)
- Approval of executive compensation package with 239.9M votes in favor (97.4% of votes cast excluding abstentions)
- Ratification of PricewaterhouseCoopers LLP as independent auditor with 334.6M votes in favor (98.5% of votes cast excluding abstentions)
Notable was the significant support for Zachary Bogue and Robert Hershberg, while Zavain Dar received relatively more withheld votes. The executive compensation proposal received strong stockholder backing, demonstrating confidence in leadership compensation structures.
FAQ
What is the current stock price of Recursion Pharmaceuticals (RXRX)?
What is the market cap of Recursion Pharmaceuticals (RXRX)?
What is the core business of Recursion Pharmaceuticals?
How does the Recursion Operating System (OS) work?
What distinguishes Recursion's business model?
In which therapeutic areas does the company focus its research?
How do partnerships play a role in Recursion's strategy?
What role does machine learning play in the company’s operations?
How does Recursion ensure scientific rigor in its processes?
What makes Recursion significant in the current biotech landscape?
